Valneva And LimmaTech Awarded FDA Fast Track Designation For Tetravalent Shigella Vaccine Candidate S4V
Portfolio Pulse from Benzinga Newsdesk
Valneva and LimmaTech have been granted FDA Fast Track Designation for their tetravalent Shigella vaccine candidate, S4V. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
October 16, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva's tetravalent Shigella vaccine candidate, S4V, has received FDA Fast Track Designation, which could accelerate its development and review process.
The FDA Fast Track Designation is significant as it can lead to expedited development and review of Valneva's vaccine candidate, potentially bringing it to market faster. This is positive news for Valneva, as it addresses a serious condition with unmet medical needs.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80